Description
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Location: REDI (East Bay)
Please Contact Nhu Tran or call 510.204.3428
Principal Investigator
Co-Investigator(s)
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Identify PCPs’ awareness of breast cancer risk assessment and breast cancer chemoprevention knowledge, and identify perceived barriers and clinic solutions.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator